ANDA 212092, held by Chartwell Molecular. Clobazam.
As of Nov 15, 2026, ANDA 212092 (Clobazam), held by Chartwell Molecular, was first approved by FDA on Oct 30, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
